|
Esophageal Varices
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
PLT count and albumin level were independently associated with medium/large EV.
|
31135449 |
2019 |
|
Esophageal Varices
|
0.090 |
Biomarker
|
disease |
BEFREE |
Child-Pugh score, the recently developed albumin-bilirubin (ALBI) grade, and the albumin-indocyanine green evaluation (ALICE) were compared to evaluate their diagnostic accuracy for the detection of esophageal varices using the area under the receiver operating characteristic curve (AUROC).
|
30358037 |
2019 |
|
Esophageal Varices
|
0.090 |
Biomarker
|
disease |
BEFREE |
Combination of albumin-bilirubin grade and platelets to predict a compensated patient with hepatocellular carcinoma who does not require endoscopic screening for esophageal varices.
|
29317268 |
2018 |
|
Esophageal Varices
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
A multivariate analysis showed that serum albumin level less than or equal to 4 g/dl (P=0.020), α-fetoprotein level greater than 20 ng/ml (P<0.001), as well as the presence of vascular invasion (P<0.001), but not the presence of EV, were independent risk factors associated with poor OS.
|
29994873 |
2018 |
|
Esophageal Varices
|
0.090 |
Biomarker
|
disease |
BEFREE |
Univariate analysis of patients taking β-blockers showed an association of PVT with grade of esophageal varices (p < 0.01), CP class (p < 0.02), AST (p < 0.03), ALT and albumin (p < 0.02), PLT count and PLT/LD (p < 0.03), longitudinal diameter of the spleen (p < 0.005), ascites (p < 0.05), portal vein (p < 0.0001) and NSBB (OR 8.1; 95% CI 1.7-38.8).
|
30107378 |
2018 |
|
Esophageal Varices
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
C-P score progression was associated with oesophageal varices (P < .001), lower serum albumin (P = .03) and cholesterol (P = .01) values, and hypergammaglobulinemia (P = .02).
|
29194934 |
2018 |
|
Esophageal Varices
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Variables found to differ significantly between patients with any grade or large and without OV included increased spleen length, increased portal vein diameter, low platelet count, and low levels of albumin or low γ-glutamyltranspeptidase (γ-GTP) values.
|
28261290 |
2017 |
|
Esophageal Varices
|
0.090 |
Biomarker
|
disease |
BEFREE |
Treatment with entecavir for 96 weeks resulted in significant improvements in serum levels of HBV DNA (P=0.002), albumin (P=0.014), cholinesterase (CHE; P=0.001), HBV DNA negativity rate (P=0.004), Child-Turcotte-Pugh score (P=0.030), alanine aminotransferase normalized rate (P=0.039), and the degree of esophageal varices liver stiffness (P=0.002) in the two groups.
|
29043000 |
2017 |
|
Esophageal Varices
|
0.090 |
Biomarker
|
disease |
BEFREE |
Independent factors predicting events were absence of SVR (hazard ratio (HR)=2.66; 95% CI: 1.32-5.54), baseline serum albumin <3.9 g per 100 ml (HR=3.06; 95% CI: 1.81-5.15), presence of esophageal varices on endoscopy (HR=2.489; 95% CI: 1.546-4).
|
20700116 |
2010 |